Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.47 USD

28.47
11,702,395

-0.05 (-0.18%)

Updated Oct 31, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.

Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

by Zacks Equity Research

Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

by Zacks Equity Research

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Markets Return to Normalcy

by Zacks Equity Research

Markets Return to Normalcy

Mark Vickery headshot

Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS

by Mark Vickery

We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

by Zacks Equity Research

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.

Pfizer (PFE) Misses Q4 Earnings Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of -8.70% and 6.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Markets Await Economic and Earnings Data

by Zacks Equity Research

Markets Await Economic and Earnings Data

J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III

by Zacks Equity Research

J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

by Zacks Equity Research

Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.

John Blank headshot

Did r/WallStreetBets Smother the Bull Market?

by John Blank

Institutional traders are taking profits off the table, respecting very rich, fully priced in, stock market valuations. However, there is a lot of risk de-leveraging and capital building going on, too.

Mark Vickery headshot

Another Big Week for Q4 Earnings, Econ News; ON Semi Beats

by Mark Vickery

Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.

Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview

by Zacks Equity Research

Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview

Benjamin Rains headshot

Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?

by Benjamin Rains

Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...

Sheraz Mian headshot

Earnings Strength and Market Weakness

by Sheraz Mian

Market volatility notwithstanding, we have to acknowledge that the fundamental backdrop, as reflected in the outlook for earnings and interest rates, remains very favorable...

Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings

by Zacks Equity Research

Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".

Personal Income Increased in December

by Zacks Equity Research

Personal Income Increased in December

Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data

by Mark Vickery

With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

by Zacks Equity Research

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $35.86, moving -1.05% from the previous trading session.

Mark Vickery headshot

Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets

by Mark Vickery

The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sweta Killa headshot

JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus

by Sweta Killa

The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.